| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a … JA Dormandy, B Charbonnel, DJA Eckland, E Erdmann, ... The Lancet 366 (9493), 1279-1289, 2005 | 5207 | 2005 |
| Basal insulin and cardiovascular and other outcomes in dysglycemia ORIGIN Trial Investigators New England Journal of Medicine 367 (4), 319-328, 2012 | 2011 | 2012 |
| n–3 Fatty acids and cardiovascular outcomes in patients with dysglycemia ORIGIN Trial Investigators New England Journal of Medicine 367 (4), 309-318, 2012 | 1105 | 2012 |
| Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular … R Wilcox, MG Bousser, DJ Betteridge, G Schernthaner, V Pirags, S Kupfer, ... Stroke 38 (3), 865-873, 2007 | 599 | 2007 |
| Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy A Bierhaus, T Fleming, S Stoyanov, A Leffler, A Babes, C Neacsu, ... Nature medicine 18 (6), 926-933, 2012 | 547 | 2012 |
| Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials N Chaturvedi, M Porta, R Klein, T Orchard, J Fuller, HH Parving, R Bilous, ... The Lancet 372 (9647), 1394-1402, 2008 | 539 | 2008 |
| Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial AK Sjølie, R Klein, M Porta, T Orchard, J Fuller, HH Parving, R Bilous, ... The Lancet 372 (9647), 1385-1393, 2008 | 532 | 2008 |
| Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials R Bilous, N Chaturvedi, AK Sjølie, J Fuller, R Klein, T Orchard, M Porta, ... Annals of internal medicine 151 (1), 11-20, 2009 | 332 | 2009 |
| Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin K Zhou, SW Yee, EL Seiser, N Van Leeuwen, R Tavendale, AJ Bennett, ... Nature genetics 48 (9), 1055-1059, 2016 | 197 | 2016 |
| Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular … HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... Diabetes, Obesity and Metabolism 20 (1), 42-49, 2018 | 196 | 2018 |
| Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and … JB Green, MA Bethel, SK Paul, A Ring, KD Kaufman, DR Shapiro, ... American heart journal 166 (6), 983-989. e7, 2013 | 179 | 2013 |
| Genome-wide association study of diabetic kidney disease highlights biology involved in glomerular basement membrane collagen RM Salem, JN Todd, N Sandholm, JB Cole, WM Chen, D Andrews, ... Journal of the American Society of Nephrology 30 (10), 2000-2016, 2019 | 152 | 2019 |
| Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side … L Tarasova, I Kalnina, K Geldnere, A Bumbure, R Ritenberga, ... Pharmacogenetics and genomics 22 (9), 659-666, 2012 | 147 | 2012 |
| Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo R Bentley-Lewis, D Aguilar, MC Riddle, B Claggett, R Diaz, K Dickstein, ... American heart journal 169 (5), 631-638. e7, 2015 | 120 | 2015 |
| Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of … HC Gerstein, RE Ratner, CP Cannon, PW Serruys, HM García-García, ... Circulation 121 (10), 1176-1187, 2010 | 118 | 2010 |
| Fatty liver index and hepatic steatosis index for prediction of non‐alcoholic fatty liver disease in type 1 diabetes L Sviklāne, E Olmane, Z Dzērve, K Kupčs, V Pīrāgs, J Sokolovska Journal of gastroenterology and hepatology 33 (1), 270-276, 2018 | 116 | 2018 |
| Variants in pharmacokinetic transporters and glycemic response to metformin: a Metgen meta‐analysis T Dujic, K Zhou, SW Yee, N van Leeuwen, CE de Keyser, M Javorský, ... Clinical Pharmacology & Therapeutics 101 (6), 763-772, 2017 | 111 | 2017 |
| Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT. LANTUS trial M Davies, F Lavalle‐González, F Storms, R Gomis, ... Diabetes, Obesity and Metabolism 10 (5), 387-399, 2008 | 106 | 2008 |
| The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics DIRECT Programme Study Group Journal of the Renin-Angiotensin-Aldosterone System 6 (1), 25-32, 2005 | 94 | 2005 |
| The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia L Bordeleau, N Yakubovich, GR Dagenais, J Rosenstock, J Probstfield, ... Diabetes care 37 (5), 1360-1366, 2014 | 86 | 2014 |
Janis KlovinsLatvian Biomedical Research and Study CentreDirección de correo verificada de biomed.lu.lv
